Vanda Pharmaceuticals Inc. (VNDA)
- Previous Close
4.6300 - Open
4.6300 - Bid 4.5400 x 300
- Ask 4.6000 x 100
- Day's Range
4.5508 - 4.6700 - 52 Week Range
3.3000 - 7.0000 - Volume
1,184,159 - Avg. Volume
2,364,491 - Market Cap (intraday)
262.371M - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
114.00 - EPS (TTM)
0.0400 - Earnings Date May 1, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.25
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
www.vandapharma.comRecent News: VNDA
Performance Overview: VNDA
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VNDA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VNDA
Valuation Measures
Market Cap
262.37M
Enterprise Value
-116.49M
Trailing P/E
114.00
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.36
Price/Book (mrq)
0.48
Enterprise Value/Revenue
-0.60
Enterprise Value/EBITDA
10.65
Financial Highlights
Profitability and Income Statement
Profit Margin
1.30%
Return on Assets (ttm)
-1.36%
Return on Equity (ttm)
0.47%
Revenue (ttm)
192.64M
Net Income Avi to Common (ttm)
2.51M
Diluted EPS (ttm)
0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
388.26M
Total Debt/Equity (mrq)
1.73%
Levered Free Cash Flow (ttm)
-88.78M
Research Analysis: VNDA
Company Insights: VNDA
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: VNDA
VNDA: Rating decreased to a SELL
VANDA PHARMACEUTICALS INC has an Investment Rating of SELL; a target price of $5.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetVNDA: What does Argus have to say about VNDA?
VANDA PHARMACEUTICALS INC has an Investment Rating of BUY; a target price of $6.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetVNDA: What does Argus have to say about VNDA?
VANDA PHARMACEUTICALS INC has an Investment Rating of BUY; a target price of $6.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetVNDA: Rating increased to a BUY
VANDA PHARMACEUTICALS INC has an Investment Rating of BUY; a target price of $6.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target